Akorn Sharpens Focus As It Divests Ophthalmic Brands

Focusing On Human Generics And Animal Care After Completing Sale To Théa Pharma

15 Mar 2022

Akorn says it is concentrating its focus on “targeted avenues of growth” – including human generics and animal care – after divesting its branded ophthalmic portfolio to Théa Pharma.

Glasses Eye Test Chart Vision Focus — Akorn is sharpening the focus of its business with the divestment of its ophthalmic brands • Source: David Izquierdo Roger / Alamy Stock Photo

Akorn says the completed divestment of its branded ophthalmic portfolio to Théa Pharma will enable the firm to focus on growth areas including human generics and animal care.

Financial details were not revealed of the transaction, which follows Akorn going through Chapter 11 bankruptcy proceedings and a sale...